Hematologic neoplasms

Inclusion Criteria

- Male or female patients aged ≥18 years
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and Life expectancy of at least 12 weeks
- Patients are able and willing to provide bone marrow biopsies/aspirates as requested by the protocol
- Patients with confirmed advanced hematological malignancies
- Negative serum pregnancy test
- Women and men of reproductive potential must agree to use highly effective contraception when sexually active.
- Ability to understand and the willingness to sign a written informed consent.
- Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤1.5 times ULN)
- Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN

Exclusion Criteria

- Presence of active/uncontrolled central nervous system involvement
- History of clinically significant cardiac disease; uncontrolled hypertension
- Left ventricular ejection fraction (LVEF) < 45%
- Allogeneic stem cell transplant within 100 days before first dose of study drug
- Known history of human immunodeficiency virus (HIV) infection
- Chronic or active hepatitis B or C, requiring antiviral therapy
- Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study
- Serious, uncontrolled infection
- Unresolved chronic toxicity > grade 1 from prior therapy
- Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study